
Chris Lauber appointed as chair of the ICTV's Nidovirales Study Group
Important position for the head of the Computational Virology research group at TWINCORE

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Important position for the head of the Computational Virology research group at TWINCORE

Two exciting days of science and networking with more than 150 participants

Long-time companion passes away at the age of 73
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Bartsch Y, Webb N, Burgess E, Kang J, Lauffenburger D, Julg B
Buttler L, Velázquez-Ramírez D, Tiede A, Conradi A, Woltemate S, Geffers R, Bremer B, Spielmann V, Kahlhöfer J, Kraft A, Schlüter D, Wedemeyer H, Cornberg M, Falk C, Vital M, Maasoumy B
Möhn N, Narten E, Duzzi L, Thomas J, Grote-Levi L, Beutel G, Fröhlich T, Bollmann B, Wirth T, von Wasielewski I, Gutzmer R, Heidel F, Pessler F, Zobl W, Schuchardt S, Ivanyi P, Nay S, Skripuletz T
In this project, antibodies that help to ward off infections are being investigated in more detail. The aim is to find characteristics that have a protective effect against certain pathogens by comparing different antibody profiles in infections and vaccinations.
We are investigating why HCV infections sometimes heal spontaneously, but often become chronic, and why RSV infections are severe in some children. We use modern sequencing technologies to analyze the genetic characteristics of hosts and pathogens in order to understand susceptibility.
Human, potentially neutralizing antibodies against HEV have advanced the development of new detection methods for the virus in patient samples. Serological and functional analyses are used to determine markers for the course and treatment of chronic infections.
Studies in the cell culture model show that only a few disinfectants are effective against HEV, which provides important information on hygiene measures for HEV infections. We are also working together to test vaccines for pigs as HEV reservoirs.

